|
|
Article: Gensia spin-off targets gene transfer therapy. (Viagene) (company profile)
- Article from:
- San Diego Business Journal
- Article date:
- December 7, 1987
- Author:
CopyrightCOPYRIGHT 1987 CBJ, L.P. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Genisa spin-off targets gene transfer therapy By RICK DOWER
Gensia Pharmaceuticals has spun off a new company to develop a noval approach known as gene transfer therapy for treating disease.
The spin-off, named Viagene, temporarily will share Gensia's Sorrento Valley office and laboratory space until it moves into its own quarters, according to Gensia President David F. Hale. Hale, the former chief executive of Hybritech Inc., will serve as Viagene's interim chief while a search for a permanent president is under way.
The new company -- whose original name, Retrogene, was recently abandoned by company officials -- is funded with an initial $1 ...